Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma

NCT03123783 is registered in ClinicalTrials.gov with Apexigen America, Inc. as lead sponsor.

NCT NCT03123783
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03123783 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma
Lead sponsor
Apexigen America, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 10, 2017
Completion date
November 16, 2020
Enrollment
140 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, melanoma, metastatic melanoma, neoplasm of lung, non small cell lung cancer metastatic